Authors
Sepideh Nazeri, Ahmad Reza Jamshidi, Mahdi Mahmoudi, Mahdi Vojdanian, Shahin Khadem Azarian, Sanaz Afraei, Shayan Mostafaei, Mostafa Hosseini, Abbas Mirshafiey
Publication date
2019/5
Journal
Pharmacological Reports
Volume
71
Pages
393-398
Publisher
Springer International Publishing
Description
Background
To assess the therapeutic efficacy, safety and tolerability of Guluronic acid (G2013) in patients with ankylosing spondylitis (AS) patients.
Methods
This investigation was a 12-week randomized, placebo-controlled, phase I/II clinical trial involving 75 AS patients that were randomly divided into 3 groups: 25 as placebo, 25 Guluronic acid and 25 naproxen groups. Patients who had AS with active disease at baseline according to the modified New York criteria were considered for this trial. The primary consequence measure was the Appraisement of Spondyloarthritis International Society (ASAS) 20 response-rate at week 12.
Results
There were no statistically significant differences between groups at the entry. ASAS20 response at week 12 was achieved (60.8%) in patients receiving Guluronic acid compared with …
Total citations
Scholar articles
S Nazeri, AR Jamshidi, M Mahmoudi, M Vojdanian… - Pharmacological Reports, 2019